News >

Tislelizumab Frontline Combos Improve PFS in Squamous NSCLC

Gina Columbus
Published: Tuesday, Jan 21, 2020

lung cancer
The anti–PD-1 agent tislelizumab (BGB-A317) in combination with chemotherapy improved progression-free survival (PFS) compared with chemotherapy alone as a first-line treatment for patients with advanced squamous non–small cell lung cancer (NSCLC), meeting the primary endpoint at a planned interim analysis of the phase III BGB-A317-307 trial (NCT03594747).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication